Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
复制标题
DOI：
10.1155/2015/367354
复制
发表时间：
2015
影响因子：
--
通讯作者：
Vaena D
中科院分区：
文献类型：
--
作者：
Raman R;Vaena D
局限性肾细胞癌(RCC)通常仅通过手术就可以治愈。然而，转移性肾癌通常是无法治愈的。在20世纪90年代，细胞因子形式的免疫治疗是转移性肾癌治疗的主要手段。然而，只有少数高度精选的患者出现了与治疗相关的实质性毒性反应。靶向药物的出现，如血管内皮生长因子酪氨酸激酶抑制剂和哺乳动物靶向雷帕霉素(MTOR)抑制剂的出现，导致了这一范式的变化，这是由于提高了应答率和无进展生存率，更好的安全性，以及口服给药的便利性。然而，大多数患者最终会进步，大约有12%的人在5年内存活。相比之下，在接受细胞因子治疗的少数患者中，观察到持续10年或更长时间的持久反应。最近，随着其他恶性肿瘤(如黑色素瘤和前列腺癌)的新免疫疗法的总存活率的提高，转移性肾细胞癌的免疫疗法重新引起了人们的兴趣。在这篇综述中，我们讨论了免疫治疗的基本原理和治疗转移性肾细胞癌的免疫治疗策略的最新进展。
Localized renal cell carcinoma (RCC) is often curable by surgery alone. However, metastatic RCC is generally incurable. In the 1990s, immunotherapy in the form of cytokines was the mainstay of treatment for metastatic RCC. However, responses were seen in only a minority of highly selected patients with substantial treatment-related toxicities. The advent of targeted agents such as vascular endothelial growth factor tyrosine kinase inhibitors VEGF-TKIs and mammalian target of rapamycin (mTOR) inhibitors led to a change in this paradigm due to improved response rates and progression-free survival, a better safety profile, and the convenience of oral administration. However, most patients ultimately progress with about 12% being alive at 5 years. In contrast, durable responses lasting 10 years or more are noted in a minority of those treated with cytokines. More recently, an improved overall survival with newer forms of immunotherapy in other malignancies (such as melanoma and prostate cancer) has led to a resurgence of interest in immune therapies in metastatic RCC. In this review we discuss the rationale for immunotherapy and recent developments in immunotherapeutic strategies for treating metastatic RCC.
登录
查看更多内容
DOI：
10.1056/nejmoa1003466
发表时间：
2010-08-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者：
Urba WJ
影响因子：
6.2
作者：
Jonasch E;Corn P;Pagliaro LC;Warneke CL;Johnson MM;Tamboli P;Ng C;Aparicio A;Ashe RG;Wright JJ;Tannir NM
通讯作者：
Tannir NM
影响因子：
11.5
作者：
Atkins, M;Regan, M;Signoretti, S
通讯作者：
Signoretti, S
影响因子：
158.5
作者：
Kantoff, Philip W.;Higano, Celestia S.;Young, J.
通讯作者：
Young, J.
影响因子：
64.8
作者：
Herbst RS;Soria JC;Kowanetz M;Fine GD;Hamid O;Gordon MS;Sosman JA;McDermott DF;Powderly JD;Gettinger SN;Kohrt HE;Horn L;Lawrence DP;Rost S;Leabman M;Xiao Y;Mokatrin A;Koeppen H;Hegde PS;Mellman I;Chen DS;Hodi FS
通讯作者：
Hodi FS